In summary, CXCR2 CAR-T cell therapy significantly improved CAR-T cell infiltration into tumor tissues and reshaped the cellular composition within the PDAC immune microenvironment, thereby enhancing antitumor effects. The gene discussed is CXCR2; the disease is neoplasm.